IQV
IQVIACNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The constructive case is that Q1 showed broad execution rather than a one-off beat: Commercial Solutions grew 11.6%, R&D Solutions grew 6.2%, free cash flow reached $491M, and management raised FY2026 adjusted EPS guidance while reaffirming revenue and EBITDA guidance [#IR-2026-05-05]. With the stock at $170.68 versus a packet median target of $234.19, there is room for recovery if backlog conversion and commercial growth hold.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.5.
What can break
Backlog conversion risk remains central; management highlighted expected 12-month conversion, but the pace at which backlog converts into revenue remains a key operating risk [#10-Q-2026-05-05].
Momentum
41
Value
66
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $188.00 · Bull $215.00 · Bear $150.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $234.19
Why
Momentum41 · Δ7d +20.2
Value66 · Δ7d -0.5
Sentiment51 · Δ7d -8.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
41
34% active weight
Current posture
7d trendImproving
Δ7d
+20.2
Δ21d
+29.9
Value
66
32% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
-0.0
Sentiment
51
33% active weight
Current posture
7d trendSoftening
Δ7d
-8.4
Δ21d
-36.6
Why this grade
Composite grade C. Momentum 40.6 / Value 65.8 / Sentiment 50.9
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$30.15B
Beta
1.37
Shares Out
170.3M
P/E (TTM)
32.2
P/S (TTM)
2.51
P/FCF (TTM)
18.07
Rev YoY
+5.2%
EPS YoY
+24.6%
Gross Margin
+33.8%
Op Margin
+13.7%
Net Debt
$12.36B
Current Ratio
0.70
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology